EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes

Matthias Dottermusch iD, Ali Biabani, Tasja Lempertz, Yannis Schumann, Jelena Navolic, Shweta Godbole, Denise Obrecht, Stephan Frank, Mario M Dorostkar, Hannah Voß, Hartmut Schlüter, Stefan Rutkowski und 2 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Matthias Dottermusch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Proteomics, Neoplasms, Germ Cell and Embryonal, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erich und Gertrud Roggenbuck-Stiftung, Fördergemeinschaft Kinderkrebszentrum Hamburg, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Embryonal tumors with multilayered rosettes (ETMR) are rare malignant embryonal brain tumors. The prognosis of ETMR is poor and novel therapeutic approaches are desperately needed. Comprehension of ETMR tumor biology is currently based on only few previous molecular studies, which mainly focused on the analyses of nucleic acids. In this study, we explored integrated ETMR proteomics.

Methods

Using mass spectrometry, proteome data were acquired from 16 ETMR and the ETMR cell line BT183. Proteome data were integrated with case-matched global DNA methylation data, publicly available transcriptome data, and proteome data of further embryonal and pediatric brain tumors.

Results

Proteome-based cluster analyses grouped ETMR samples according to histomorphology, separating neuropil-rich tumors with neuronal signatures from primitive tumors with signatures relating to stemness and chromosome organization. Integrated proteomics showcased that ETMR and BT183 cells harbor proteasome regulatory proteins in abundance, implicating their strong dependency on the proteasome machinery to safeguard proteostasis. Indeed, in vitro assays using BT183 highlighted that ETMR tumor cells are highly vulnerable toward treatment with the CNS penetrant proteasome inhibitor Marizomib.

Conclusions

In summary, histomorphology stipulates the proteome signatures of ETMR, and proteasome regulatory proteins are pervasively abundant in these tumors. As validated in vitro, proteasome inhibition poses a promising therapeutic option in ETMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome Endopeptidase ComplexProteomicsNeoplasms, Germ Cell and EmbryonalBrain NeoplasmsHumansProteomeBiomarkers, TumorProteasome InhibitorsDNA Methylation

Stichwörter der Autor:innen

DNA methylationembryonal tumor with multilayered rosettesproteasomeproteometranscriptome

Substanzen

Proteasome Endopeptidase ComplexProteomeBiomarkers, TumorProteasome Inhibitors

Autor:innen und Institutionen

  • Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Section of Mass Spectrometric Proteomics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Chair for High Performance Computing, Helmut-Schmidt University, Hamburg, Germany.
  • Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.

ORCID-Profile: Matthias Dottermusch, Ulrich Schüller, Julia E Neumann

Förderung

  • Erich und Gertrud Roggenbuck-Stiftung
  • Fördergemeinschaft Kinderkrebszentrum Hamburg
  • Deutsche Forschungsgemeinschaft
  • Hamburger Krebsgesellschaft e.V.

Zitieren

APA

Dottermusch, M., Biabani, A., Lempertz, T., Schumann, Y., Navolic, J., Godbole, S., Obrecht, D., Frank, S., Dorostkar, M. M., Voß, H., Schlüter, H., Rutkowski, S., Schüller, U., & Neumann, J. E. (2024). Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad265

Vancouver

Dottermusch M, Biabani A, Lempertz T, Schumann Y, Navolic J, Godbole S, et al. Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad265

BibTeX
@article{Dottermusch2024,
  author = {Dottermusch, Matthias and Biabani, Ali and Lempertz, Tasja and Schumann, Yannis and Navolic, Jelena and Godbole, Shweta and Obrecht, Denise and Frank, Stephan and Dorostkar, Mario M and Voß, Hannah and Schlüter, Hartmut and Rutkowski, Stefan and Schüller, Ulrich and Neumann, Julia E},
  title = {Integrated proteomics spotlight the proteasome as a therapeutic vulnerability in embryonal tumors with multilayered rosettes},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad265}
}
Kostenlos starten →